Alveolar Soft Part Sarcoma Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Alveolar Soft Part Sarcoma.
Found 1 Approved Drug for Alveolar Soft Part Sarcoma
Atezolizumab
Brand Names
Tecentriq, Tecentriq Hybreza
Atezolizumab
Brand Names
Tecentriq, Tecentriq Hybreza
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: May 18, 2016
Classification: Endoglycosidase
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances